Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SLNO 
Soleno Therapeutics Inc (SLNO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: SLNO (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $118.73
1 Year Target Price $118.73
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 215.96% | Avg. Invested days 65 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.85B USD | Price to earnings Ratio - | 1Y Target Price 118.73 |
Price to earnings Ratio - | 1Y Target Price 118.73 | ||
Volume (30-day avg) 8 | Beta -2.72 | 52 Weeks Range 41.50 - 90.32 | Updated Date 09/15/2025 |
52 Weeks Range 41.50 - 90.32 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -16.61% |
Management Effectiveness
Return on Assets (TTM) -36.6% | Return on Equity (TTM) -69.53% |
Valuation
Trailing PE - | Forward PE 22.32 | Enterprise Value 2615563382 | Price to Sales(TTM) 87.26 |
Enterprise Value 2615563382 | Price to Sales(TTM) 87.26 | ||
Enterprise Value to Revenue 80.09 | Enterprise Value to EBITDA 0.02 | Shares Outstanding 53145000 | Shares Floating 44870863 |
Shares Outstanding 53145000 | Shares Floating 44870863 | ||
Percent Insiders 1.79 | Percent Institutions 110.34 |
Upturn AI SWOT
Soleno Therapeutics Inc
Company Overview
History and Background
Soleno Therapeutics Inc. is a biopharmaceutical company founded in 2011. They are focused on developing and commercializing novel therapeutics for the treatment of rare diseases. Key milestones include advancing Diazoxide Choline Controlled Release (DCCR) towards regulatory approval.
Core Business Areas
- Rare Disease Therapeutics: Focused on developing and commercializing DCCR for Prader-Willi Syndrome (PWS).
Leadership and Structure
The leadership team is headed by the CEO, with various VPs overseeing clinical development, regulatory affairs, and other functional areas. The organizational structure is typical of a small, publicly traded biotech company.
Top Products and Market Share
Key Offerings
- Diazoxide Choline Controlled Release (DCCR): DCCR is Soleno's lead product candidate for the treatment of Prader-Willi Syndrome (PWS). There is no currently approved product for PWS in the US market, so it would target 100% of the medication market share if approved. Competitors: No direct competitors with an approved therapy; therapies focus on specific symptoms (behavioral, endocrine).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated, with a focus on innovation and addressing unmet medical needs in rare diseases.
Positioning
Soleno Therapeutics is positioned as a leader in developing a potential treatment for Prader-Willi Syndrome (PWS), a rare genetic disorder.
Total Addressable Market (TAM)
The estimated TAM for a PWS treatment is significant given the lack of approved therapies. Estimates range from $500 million to $1 billion annually. Soleno is positioned to capture a substantial portion of this market if DCCR is approved.
Upturn SWOT Analysis
Strengths
- Lead product candidate targeting an unmet medical need
- Orphan drug designation
- Experienced management team
Weaknesses
- Reliance on a single product candidate
- Small market capitalization
- Dependence on regulatory approval
- History of operating losses
Opportunities
- Potential for FDA approval of DCCR
- Expansion into other indications
- Strategic partnerships
- Acquisition by a larger pharmaceutical company
Threats
- Regulatory setbacks
- Clinical trial failures
- Competition from other emerging therapies
- Financing risks
Competitors and Market Share
Key Competitors
- No direct competitors with approved therapies. Companies developing treatments for associated conditions or symptoms: ZGNX
- TRVN
Competitive Landscape
Soleno possesses a first-mover advantage, if approved, due to a lack of direct competitors for PWS. Companies such as ZGNX and TRVN are focused on other ailments. Soleno is dependent on getting their drug approved.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been limited due to the lack of commercial products. Growth is dependent on future product development.
Future Projections: Future growth depends on the approval and commercialization of DCCR. Analyst estimates vary based on the perceived likelihood of approval.
Recent Initiatives: Recent initiatives include completing and submitting the NDA for DCCR to the FDA, securing financing, and preparing for potential commercialization.
Summary
Soleno Therapeutics is a high-risk, high-reward biopharmaceutical company focused on an unmet medical need. Their strength lies in the potential of DCCR to treat PWS. They face challenges related to regulatory approval, financing, and competition from symptom-treating therapies. The future success is tightly coupled to DCCR's approval and subsequent commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Analyst reports
- Company press releases
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data and market estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Soleno Therapeutics Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-11-13 | Chairman, President, CEO & COO Dr. Anish Bhatnagar M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 133 | Website https://soleno.life |
Full time employees 133 | Website https://soleno.life | ||
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.